EVOTEC

EVOTEC, founded in 1993, is a global drug discovery and development company committed to discovering and delivering highly effective therapeutics to patients worldwide. Operating as a data-driven, multimodality platform, EVOTEC leverages innovative technologies for both proprietary research and strategic partnerships. The company focuses on developing first-in-class and best-in-class pharmaceutical products, integrating advanced scientific capabilities and cutting-edge technologies to address critical unmet medical needs. Its mission is to accelerate the journey from discovery to market for novel medicines, fostering innovation across the life sciences sector.

With a substantial global footprint, EVOTEC operates across 14 locations and employs between 1,000 and 5,000 professionals. This extensive network supports its comprehensive drug discovery and development services, encompassing early-stage research, preclinical development, and manufacturing. The company's operational scale and technological infrastructure are designed to drive scientific breakthroughs and deliver high-quality outcomes for its partners. To gain insight into the expertise and leadership driving these advancements, you can Meet EVOTEC's team.

EVOTEC reported a revenue of $886.1M. The company has a robust history of financial activities, including significant debt financing from the European Investment Bank and private equity investments from entities like Mubadala and Novo Holdings. These financial strategies support its ongoing research and development initiatives and expansion efforts. For a detailed overview of its financial performance and investment history, interested parties can Explore financial highlights. EVOTEC's ticker symbol is NASDAQ: EVO.